Kyowa Kirin is committed to ensuring that there is no modern slavery or human trafficking in our supply chains or in any part of our business. We are committed to acting ethically and with integrity in all of our business relationships and to implementing and enforcing effective systems and controls to ensure slavery and human trafficking is not taking place in any of our supply chains. We have a zero tolerance to slavery and human trafficking.
This statement is made by Kyowa Kirin International plc (“KKI”) and its subsidiaries which include:
- Strakan International SA
- Kyowa Kirin Services Limited
- Kyowa Kirin Sàrl
- Kyowa Kirin Holdings B.V.
- Kyowa Kirin Limited
- Kyowa Kirin Pharmaceutical Development Limited
- Kyowa Kirin Ireland Limited
- Kyowa Kirin Pharma s.r.o
- Kyowa Kirin Pharma FZ-LLC
- Kyowa Kirin GmbH
- Kyowa Kirin AB
- Kyowa Kirin Pharma B.V.
- Kyowa Kirin S.r.l.
- Kyowa Kirin Holdings B.V., French PE
- Kyowa Kirin Pharma SAS
- Kyowa Kirin Farmacéutica, S.L.U.
- Kyowa Kirin Austria GmbH
- Kyowa Kirin Farmacêutica, Unipessoal Lda.
- Kyowa Kirin Pharma S.R.L.
- Archimedes Pharma Limited
- Archimedes Pharma UK Ltd
pursuant to Section 54(1) of the Modern Slavery Act 2015 (the “Act”) and covers the financial year ending 31 December 2019. KKI is a wholly owned subsidiary of Kyowa Kirin Co., Ltd. a company incorporated in Japan and listed on the Tokyo Stock Exchange.
The Kyowa Kirin Group is an R&D based pharmaceutical company with special strengths in biotechnology. The Kyowa Kirin Group strives to contribute to the health and well-being of people around the world, by creating new value through the pursuit of advances in life sciences and technologies.
KKI has its head office in the UK and trading companies across Europe and the GCCmarketing and distributing our pharmaceutical products.
Our Supply Chains
KKI outsources its manufacturing and packaging requirements to third parties, including the supply of active pharmaceutical ingredients.
KKI operates an ongoing supply chain surveillance exercise in order to ensure that our third party suppliers do not engage in any activities or behaviour in contravention of the Act. This includes:
- Receiving written, binding confirmation from our suppliers that they are operating in alignment with the Act;
- Ensuring that new supplier contracts include reference to the Act, and existing contracts are amended to do so at the earliest opportunity;
- Regularly reviewing ongoing compliance with the Act as part of our standard supplier Business Review Meetings; and
- Including compliance with the Act as part of our internal supplier Risk Management Assessment processes.
This Modern Slavery Act Transparency Statement was approved by the Board of Directors of Kyowa Kirin International plc on 15 June 2020.
Abdul Mullick
President, Kyowa Kirin International plc